3 completed, 3 terminated, 3 unknown, 1 not yet recruiting. 10 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 3, Terminated 3, Unknown 3, Not yet recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow HBV: new trials by email Literature Review of HBV trials Research Report on HBV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome Nivolumab and Ipilimumab - NSCLC Stage IV, HIV | Phase 2 | Not yet recruiting | Universita di Verona | 105 | 2023-02-01 | 2022-10-28 |
| Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen IMIQUIMOD cream, HEPATITIS B SURFACE ANTIGEN - Cirrhosis, Liver, Vaccination Failure | Phase 2 | Unknown | Central Hospital, Nancy, France | 60 | 2021-11-01 | 2021-08-31 |
| A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B APG-1387, Entecavir 0.5 mg - Hepatitis B, Chronic Hep B | Phase 2 | Unknown | Ascentage Pharma Group Inc. | 122 | 2020-06-03 | 2021-08-26 |
| Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus Inarigivir soproxil, Tenofovir alafenamide fumarate (TAF) - Hepatitis B, HBV | Phase 2 | Terminated | F-star Therapeutics, Inc. | 5 | 2019-10-10 | 2020-07-21 |
| Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor Inarigivir soproxil, Nucleoside/nucleotide (NUC) analogue inhibitors - Hepatitis B, HBV | Phase 2 | Terminated | F-star Therapeutics, Inc. | 64 | 2019-06-18 | 2020-07-22 |
| Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients inarigivir soproxil - HBV, Hepatitis B | Phase 2 | Terminated | F-star Therapeutics, Inc. | 8 | 2019-04-11 | 2020-04-29 |
| A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B Antroquinonol, placebo - HBV | Phase 2 | Completed | Golden Biotechnology Corporation | 60 | 2018-02-12 | 2026-10-19 |
| A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses Engerix B, Fendrix - HIV, Communicable Diseases | Phase 2 / Phase 3 | Completed | Sheffield Teaching Hospitals NHS Foundation Trust | 13 | 2015-07-23 | 2022-09-29 |
| Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma Transarterial Chemoembolization (TACE), Sorafenib in combination with TACE - PHENYTOIN/SORAFENIB [VA Drug Interaction], Liver Neoplasms | Phase 2 | Unknown | Shandong Cancer Hospital and Institute | 40 | 2012-05-01 | 2012-04-25 |
| Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials Entecavir, Lamivudine - Hepatitis B Virus, HBV | Phase 2 | Completed | Bristol-Myers Squibb | 1053 | 2001-01-01 | 2012-08-23 |
Hepatitis B (6) · Hepatitis B, Chronic (4) · Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Communicable Diseases (1) · Digestive System Neoplasms (1) · Liver Cirrhosis (1) · Liver Diseases (1) · Liver Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Post-Acute COVID-19 Syndrome (1)
Digestive System Diseases (8) · Infections (7) · Liver Diseases (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Virus Diseases (7) · Blood-Borne Infections (6) · DNA Virus Infections (6) · Disease Attributes (6) · Hepadnaviridae Infections (6) · Hepatitis (6) · Hepatitis, Viral, Human (6) · Chronic Disease (5) · Communicable Diseases (5) · Hepatitis, Chronic (4)
entecavir (2) · APG-1387 (1) · Engerix-B (1) · Fendrix (1) · Hepatitis B Surface Antigens (1) · Ipilimumab (1) · Lamivudine (1) · Nivolumab (1) · Nucleobindins (1) · Nucleosides (1) · Nucleotides (1) · Sorafenib (1) · antroquinonol (1) · tenofovir alafenamide (1)
F-star Therapeutics, Inc. (3) · Ascentage Pharma Group Inc. (1) · Bristol-Myers Squibb (1) · Central Hospital, Nancy, France (1) · Golden Biotechnology Corporation (1) · Shandong Cancer Hospital and Institute (1) · Sheffield Teaching Hospitals NHS Foundation Trust (1) · Universita di Verona (1)
China (2) · United Kingdom (2) · Canada (1) · Hong Kong (1) · Italy (1) · Singapore (1) · Taiwan (1)
Don Mitchell (2) · Cheng-Chung Wei, MD (1) · Ching-Pin Lin, MD (1) · Jinlong Song, MD (1) · Prof. Lim Seng Gee (1) · Yifan Zhai, MD, PhD (1)